AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

CORRECTING and REPLACING - Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021 GMT

MENLO PARK, Calif.--(BUSINESS WIRE)--Jan 5, 2021--

Presentation time in the release dated December 17, 2020, should read 2 p.m. ET (instead of 5 p.m. ET).

The updated release reads:

INTERSECT ENT TO PRESENT AT THE 39 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the 39 th Annual J.P. Morgan Healthcare Conference. Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will present at 2:00 p.m. ET / 11:00 a.m. PT on Tuesday, January 12, 2021.

ADVERTISEMENT

A live webcast of the presentation can be accessed by visiting the “Investor Relations” page of the Company’s website at www.intersectENT.com. A replay will be available on the Company’s website following the event.

About Intersect ENT

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings that complement the Company’s PROPEL ® and SINUVA ® sinus implants and extend its geographic reach.

For additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com. For more information about PROPEL ® (mometasone furoate) sinus implants and SINUVA ® (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com.

ADVERTISEMENT

Intersect ENT ®, PROPEL ® and SINUVA ® are registered trademarks of Intersect ENT, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20201217006091/en/

CONTACT: Intersect ENT, Inc.

Randy Meier, 650-641-2105

ir@intersectENT.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH MEDICAL DEVICES

SOURCE: Intersect ENT, Inc.

Copyright Business Wire 2021.

PUB: 01/05/2021 08:00 AM/DISC: 01/05/2021 08:01 AM

http://www.businesswire.com/news/home/20201217006091/en